SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer

Jeffrey J. Leow, Jens Bedke, Karim Chamie, Justin W. Collins, Siamak Daneshmand, Petros Grivas, Axel Heidenreich, Edward M. Messing, Trevor J. Royce, Alexander I. Sankin, Mark P. Schoenberg, William U. Shipley, Arnauld Villers, Jason A. Efstathiou, Joaquim Bellmunt, Arnulf Stenzl

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To provide a comprehensive overview and update of the Joint Société Internationale d’Urologie–International Consultation on Urological Diseases (SIU–ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC). Methods: Contemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine. Results: Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3–4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation. Conclusion: A multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.

Original languageEnglish (US)
Pages (from-to)61-83
Number of pages23
JournalWorld Journal of Urology
Volume37
Issue number1
DOIs
StatePublished - Jan 23 2019

Fingerprint

Muscle Neoplasms
Urologic Diseases
Urinary Bladder Neoplasms
Cystectomy
Referral and Consultation
Combination Drug Therapy
Cisplatin
Urinary Bladder
Literature
Perioperative Care
Neoadjuvant Therapy
Evidence-Based Medicine
Therapeutics
Standard of Care
Nutritional Status
Immunotherapy
Survival Rate
Joints
Guidelines
Radiation

Keywords

  • Adjuvant chemotherapy
  • Bladder-sparing
  • Chemoradiation
  • Enhanced recovery after surgery
  • Muscle-invasive bladder cancer
  • Neoadjuvant chemotherapy
  • Radical cystectomy
  • Transurethral resection of bladder tumor
  • Trimodal
  • Urothelial carcinoma of bladder
  • Variant histology

ASJC Scopus subject areas

  • Urology

Cite this

Leow, J. J., Bedke, J., Chamie, K., Collins, J. W., Daneshmand, S., Grivas, P., ... Stenzl, A. (2019). SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 37(1), 61-83. https://doi.org/10.1007/s00345-018-2606-y

SIU–ICUD consultation on bladder cancer : treatment of muscle-invasive bladder cancer. / Leow, Jeffrey J.; Bedke, Jens; Chamie, Karim; Collins, Justin W.; Daneshmand, Siamak; Grivas, Petros; Heidenreich, Axel; Messing, Edward M.; Royce, Trevor J.; Sankin, Alexander I.; Schoenberg, Mark P.; Shipley, William U.; Villers, Arnauld; Efstathiou, Jason A.; Bellmunt, Joaquim; Stenzl, Arnulf.

In: World Journal of Urology, Vol. 37, No. 1, 23.01.2019, p. 61-83.

Research output: Contribution to journalArticle

Leow, JJ, Bedke, J, Chamie, K, Collins, JW, Daneshmand, S, Grivas, P, Heidenreich, A, Messing, EM, Royce, TJ, Sankin, AI, Schoenberg, MP, Shipley, WU, Villers, A, Efstathiou, JA, Bellmunt, J & Stenzl, A 2019, 'SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer', World Journal of Urology, vol. 37, no. 1, pp. 61-83. https://doi.org/10.1007/s00345-018-2606-y
Leow, Jeffrey J. ; Bedke, Jens ; Chamie, Karim ; Collins, Justin W. ; Daneshmand, Siamak ; Grivas, Petros ; Heidenreich, Axel ; Messing, Edward M. ; Royce, Trevor J. ; Sankin, Alexander I. ; Schoenberg, Mark P. ; Shipley, William U. ; Villers, Arnauld ; Efstathiou, Jason A. ; Bellmunt, Joaquim ; Stenzl, Arnulf. / SIU–ICUD consultation on bladder cancer : treatment of muscle-invasive bladder cancer. In: World Journal of Urology. 2019 ; Vol. 37, No. 1. pp. 61-83.
@article{f1933507ab394991bd703bd6967649fa,
title = "SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer",
abstract = "Purpose: To provide a comprehensive overview and update of the Joint Soci{\'e}t{\'e} Internationale d’Urologie–International Consultation on Urological Diseases (SIU–ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC). Methods: Contemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine. Results: Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3–4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation. Conclusion: A multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.",
keywords = "Adjuvant chemotherapy, Bladder-sparing, Chemoradiation, Enhanced recovery after surgery, Muscle-invasive bladder cancer, Neoadjuvant chemotherapy, Radical cystectomy, Transurethral resection of bladder tumor, Trimodal, Urothelial carcinoma of bladder, Variant histology",
author = "Leow, {Jeffrey J.} and Jens Bedke and Karim Chamie and Collins, {Justin W.} and Siamak Daneshmand and Petros Grivas and Axel Heidenreich and Messing, {Edward M.} and Royce, {Trevor J.} and Sankin, {Alexander I.} and Schoenberg, {Mark P.} and Shipley, {William U.} and Arnauld Villers and Efstathiou, {Jason A.} and Joaquim Bellmunt and Arnulf Stenzl",
year = "2019",
month = "1",
day = "23",
doi = "10.1007/s00345-018-2606-y",
language = "English (US)",
volume = "37",
pages = "61--83",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - SIU–ICUD consultation on bladder cancer

T2 - treatment of muscle-invasive bladder cancer

AU - Leow, Jeffrey J.

AU - Bedke, Jens

AU - Chamie, Karim

AU - Collins, Justin W.

AU - Daneshmand, Siamak

AU - Grivas, Petros

AU - Heidenreich, Axel

AU - Messing, Edward M.

AU - Royce, Trevor J.

AU - Sankin, Alexander I.

AU - Schoenberg, Mark P.

AU - Shipley, William U.

AU - Villers, Arnauld

AU - Efstathiou, Jason A.

AU - Bellmunt, Joaquim

AU - Stenzl, Arnulf

PY - 2019/1/23

Y1 - 2019/1/23

N2 - Purpose: To provide a comprehensive overview and update of the Joint Société Internationale d’Urologie–International Consultation on Urological Diseases (SIU–ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC). Methods: Contemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine. Results: Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3–4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation. Conclusion: A multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.

AB - Purpose: To provide a comprehensive overview and update of the Joint Société Internationale d’Urologie–International Consultation on Urological Diseases (SIU–ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC). Methods: Contemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine. Results: Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3–4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation. Conclusion: A multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.

KW - Adjuvant chemotherapy

KW - Bladder-sparing

KW - Chemoradiation

KW - Enhanced recovery after surgery

KW - Muscle-invasive bladder cancer

KW - Neoadjuvant chemotherapy

KW - Radical cystectomy

KW - Transurethral resection of bladder tumor

KW - Trimodal

KW - Urothelial carcinoma of bladder

KW - Variant histology

UR - http://www.scopus.com/inward/record.url?scp=85060763999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060763999&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2606-y

DO - 10.1007/s00345-018-2606-y

M3 - Article

C2 - 30684034

AN - SCOPUS:85060763999

VL - 37

SP - 61

EP - 83

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 1

ER -